Completed
Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
NCT00251394
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
- Locations
-
- Massachusetts General Hospital Boston, Massachusetts, United States
- Brigham and Women's Hospital Boston, Massachusetts, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States